• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Gag-protease 共进化分析定义了 HIV-1 基质和衣壳中与蛋白酶抑制剂耐药性相关的新型结构表面。

Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors.

机构信息

Lifesequencing SL, Paterna, Spain.

Universidad Catolica de Valencia, Valencia, Spain.

出版信息

Sci Rep. 2017 Jun 16;7(1):3717. doi: 10.1038/s41598-017-03260-4.

DOI:10.1038/s41598-017-03260-4
PMID:28623276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5473930/
Abstract

Despite the major role of Gag in establishing resistance of HIV-1 to protease inhibitors (PIs), very limited data are available on the total contribution of Gag residues to resistance to PIs. To identify in detail Gag residues and structural interfaces associated with the development of HIV-1 resistance to PIs, we traced viral evolution under the pressure of PIs using Gag-protease single genome sequencing and coevolution analysis of protein sequences in 4 patients treated with PIs over a 9-year period. We identified a total of 38 Gag residues correlated with the protease, 32 of which were outside Gag cleavage sites. These residues were distributed in 23 Gag-protease groups of coevolution, with the viral matrix and the capsid represented in 87% and 52% of the groups. In addition, we uncovered the distribution of Gag correlated residues in specific protein surfaces of the inner face of the viral matrix and at the Cyclophilin A binding loop of the capsid. In summary, our findings suggest a tight interdependency between Gag structural proteins and the protease during the development of resistance of HIV-1 to PIs.

摘要

尽管 Gag 在建立 HIV-1 对蛋白酶抑制剂(PIs)的耐药性方面起着重要作用,但关于 Gag 残基对 PIs 耐药性的总贡献,数据非常有限。为了详细确定与 HIV-1 对 PIs 耐药性发展相关的 Gag 残基和结构界面,我们使用 Gag-蛋白酶单基因组测序和 4 名接受 PIs 治疗超过 9 年的患者的蛋白质序列共进化分析,追踪了在 PIs 压力下病毒的进化。我们总共鉴定了 38 个与蛋白酶相关的 Gag 残基,其中 32 个位于 Gag 切割位点之外。这些残基分布在 23 个 Gag-蛋白酶共进化组中,其中病毒基质和衣壳分别占 87%和 52%。此外,我们还揭示了 Gag 相关残基在病毒基质内部表面特定蛋白质表面和衣壳环孢素 A 结合环中的分布。总之,我们的研究结果表明,在 HIV-1 对 PIs 的耐药性发展过程中,Gag 结构蛋白与蛋白酶之间存在紧密的相互依存关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/0d0d32cfae12/41598_2017_3260_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/7b54e8a41df3/41598_2017_3260_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/1f2174617687/41598_2017_3260_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/5d62b8ede4c2/41598_2017_3260_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/b1f7421e7ccf/41598_2017_3260_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/0d0d32cfae12/41598_2017_3260_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/7b54e8a41df3/41598_2017_3260_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/1f2174617687/41598_2017_3260_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/5d62b8ede4c2/41598_2017_3260_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/b1f7421e7ccf/41598_2017_3260_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d989/5473930/0d0d32cfae12/41598_2017_3260_Fig5_HTML.jpg

相似文献

1
Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors.Gag-protease 共进化分析定义了 HIV-1 基质和衣壳中与蛋白酶抑制剂耐药性相关的新型结构表面。
Sci Rep. 2017 Jun 16;7(1):3717. doi: 10.1038/s41598-017-03260-4.
2
Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.对全长 HIV-1 Gag 多聚蛋白进行建模揭示了其 p6 亚基在病毒成熟中的作用,以及蛋白酶耐药性中非切割位点突变的影响。
J Biomol Struct Dyn. 2018 Dec;36(16):4366-4377. doi: 10.1080/07391102.2017.1417160. Epub 2017 Dec 27.
3
HIV-1 protease-substrate coevolution in nelfinavir resistance.奈非那韦耐药中HIV-1蛋白酶与底物的共同进化
J Virol. 2014 Jul;88(13):7145-54. doi: 10.1128/JVI.00266-14. Epub 2014 Apr 9.
4
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.HIV-1 蛋白酶、Gag 和 gp41 基线替换与基于 PI 的方案的病毒学应答相关。
J Antimicrob Chemother. 2019 Jun 1;74(6):1679-1692. doi: 10.1093/jac/dkz043.
5
Deep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and protease.对蛋白酶抑制剂耐药的HIV患者分离株进行深度测序,揭示了Gag和蛋白酶中相关突变的模式。
PLoS Comput Biol. 2015 Apr 20;11(4):e1004249. doi: 10.1371/journal.pcbi.1004249. eCollection 2015 Apr.
6
Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.1型艾滋病病毒CRF01_AE毒株的Gag和蛋白酶中氨基酸变异对病毒对蛋白酶抑制剂药物敏感性的影响。
J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):320-8. doi: 10.1097/QAI.0b013e3181b4b18c.
7
Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs.回顾蛋白酶抑制剂耐药性中的 HIV-1 Gag 突变:对可能的新型 Gag 抑制剂设计的启示。
Molecules. 2019 Sep 6;24(18):3243. doi: 10.3390/molecules24183243.
8
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.人类免疫缺陷病毒1型感染的母婴中,HIV-1蛋白酶、Gag p7和p6以及gag/pol多蛋白内蛋白酶切割位点的自然变异:无蛋白酶抑制剂情况下的氨基酸替代
Virology. 1996 May 15;219(2):407-16. doi: 10.1006/viro.1996.0266.
9
Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.正向选择压力在携带主要蛋白酶抗性突变的1型人类免疫缺陷病毒的Gag裂解位点引入二次突变。
J Virol. 2009 Sep;83(17):8916-24. doi: 10.1128/JVI.00003-09. Epub 2009 Jun 10.
10
Human Immunodeficiency Virus Gag and protease: partners in resistance.人类免疫缺陷病毒 Gag 和蛋白酶:耐药的伙伴。
Retrovirology. 2012 Aug 6;9:63. doi: 10.1186/1742-4690-9-63.

引用本文的文献

1
Subtype-Specific HIV-1 Protease and the Role of Hinge and Flap Dynamics in Drug Resistance: A Subtype C Narrative.特定亚型的HIV-1蛋白酶以及铰链区和瓣区动力学在耐药性中的作用:C亚型的阐述
Viruses. 2025 Jul 26;17(8):1044. doi: 10.3390/v17081044.
2
Susceptibility to Lenacapavir Among Newly Diagnosed HIV-Positive Patients Followed Up in Mozambique That Presented With Primary Antiretroviral Resistance to Other Classes.在莫桑比克接受随访的新诊断出的HIV阳性患者中,对其他类别药物存在原发性抗逆转录病毒耐药性的患者对来那卡韦的敏感性。
J Med Virol. 2025 Mar;97(3):e70317. doi: 10.1002/jmv.70317.
3
HIV-1 envelope facilitates the development of protease inhibitor resistance through acquiring mutations associated with viral entry and immune escape.

本文引用的文献

1
Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.顺磁核磁共振揭示的瞬时HIV-1 Gag蛋白酶相互作用提示补偿性耐药突变的起源。
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12456-12461. doi: 10.1073/pnas.1615342113. Epub 2016 Oct 17.
2
Epistasis and Pleiotropy Affect the Modularity of the Genotype-Phenotype Map of Cross-Resistance in HIV-1.上位性和多效性影响HIV-1交叉耐药性基因型-表型图谱的模块性。
Mol Biol Evol. 2016 Dec;33(12):3213-3225. doi: 10.1093/molbev/msw206. Epub 2016 Sep 27.
3
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
HIV-1包膜蛋白通过获得与病毒进入和免疫逃逸相关的突变,促进蛋白酶抑制剂耐药性的产生。
Front Microbiol. 2024 Apr 18;15:1388729. doi: 10.3389/fmicb.2024.1388729. eCollection 2024.
4
Selection among site-dependent structurally constrained substitution models of protein evolution by approximate Bayesian computation.基于近似贝叶斯计算的蛋白质进化中依赖于位置的结构约束替代模型的选择。
Bioinformatics. 2024 Mar 4;40(3). doi: 10.1093/bioinformatics/btae096.
5
Antiretroviral Imprints and Genomic Plasticity of HIV-1 in Non-clade B: Implications for Treatment.非B亚型HIV-1的抗逆转录病毒印记与基因组可塑性:对治疗的影响
Front Microbiol. 2022 Feb 9;12:812391. doi: 10.3389/fmicb.2021.812391. eCollection 2021.
6
Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors.导致 HIV-1 病毒血症非进展者 CD4 稳态丧失的病毒和细胞因素。
J Virol. 2022 Jan 12;96(1):e0149921. doi: 10.1128/JVI.01499-21. Epub 2021 Oct 20.
7
Elasticity-Associated Functionality and Inhibition of the HIV Protease.弹性相关功能和 HIV 蛋白酶的抑制作用。
Adv Exp Med Biol. 2022;1371:79-108. doi: 10.1007/5584_2021_655.
8
The impact of Gag non-cleavage site mutations on HIV-1 viral fitness from integrative modelling and simulations.基于整合建模与模拟研究Gag非切割位点突变对HIV-1病毒适应性的影响
Comput Struct Biotechnol J. 2020 Dec 23;19:330-342. doi: 10.1016/j.csbj.2020.12.022. eCollection 2021.
9
Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.核衣壳蛋白前体NCp9和NCp15抑制HIV-1逆转录酶对AZT终止引物的ATP介导的挽救作用。
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00958-20.
10
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.仅 HIV-1 Gag 突变就足以降低强化蛋白酶抑制剂治疗病毒学失败时对达芦那韦的敏感性。
J Antimicrob Chemother. 2020 Sep 1;75(9):2535-2546. doi: 10.1093/jac/dkaa228.
在接受基于蛋白酶抑制剂治疗失败的儿科患者中,Gag和蛋白酶对HIV-1表型耐药性的作用。
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2248-56. doi: 10.1128/AAC.02682-15. Print 2016 Apr.
4
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.在SARA试验中蛋白酶抑制剂单药治疗失败后,未出现主要蛋白酶突变但药物敏感性降低的证据。
PLoS One. 2015 Sep 18;10(9):e0137834. doi: 10.1371/journal.pone.0137834. eCollection 2015.
5
Deep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and protease.对蛋白酶抑制剂耐药的HIV患者分离株进行深度测序,揭示了Gag和蛋白酶中相关突变的模式。
PLoS Comput Biol. 2015 Apr 20;11(4):e1004249. doi: 10.1371/journal.pcbi.1004249. eCollection 2015 Apr.
6
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.在临床实践中,使用增效后的蛋白酶抑制剂进行单药治疗作为一种 ART 简化策略。
J Antimicrob Chemother. 2015 Apr;70(4):1124-9. doi: 10.1093/jac/dku509. Epub 2014 Dec 18.
7
The role of matrix in HIV-1 envelope glycoprotein incorporation.基质在HIV-1包膜糖蛋白掺入中的作用。
Trends Microbiol. 2014 Jul;22(7):372-8. doi: 10.1016/j.tim.2014.04.012. Epub 2014 Jun 2.
8
Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure.全球拯救HIV-1包膜糖蛋白整合缺陷:对基质结构的影响
PLoS Pathog. 2013;9(11):e1003739. doi: 10.1371/journal.ppat.1003739. Epub 2013 Nov 14.
9
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.多步抑制解释了 HIV-1 蛋白酶抑制剂的药效动力学和耐药性。
J Clin Invest. 2013 Sep;123(9):3848-60. doi: 10.1172/JCI67399. Epub 2013 Aug 27.
10
Extreme genetic fragility of the HIV-1 capsid.HIV-1 衣壳的极端遗传脆弱性。
PLoS Pathog. 2013;9(6):e1003461. doi: 10.1371/journal.ppat.1003461. Epub 2013 Jun 20.